125 i]-labeled neurotrophic factors recombinant human (rh) epo Search Results


125 i]-labeled neurotrophic factors recombinant human (rh) epo  (Cell Sciences Inc)
90
Cell Sciences Inc 125 i]-labeled neurotrophic factors recombinant human (rh) epo
(A) Intranasal delivery in nM of <t>BDNF</t> 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).
125 I] Labeled Neurotrophic Factors Recombinant Human (Rh) Epo, supplied by Cell Sciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/125+i%5D-labeled+neurotrophic+factors+recombinant+human+(rh)+epo/125+i++labeled+neurotrophic+factors+recombinant+human++rh++epo/pmc03732751-105-3-29
Average 90 stars, based on 1 article reviews
125 i]-labeled neurotrophic factors recombinant human (rh) epo - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


(A) Intranasal delivery in nM of BDNF 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: (A) Intranasal delivery in nM of BDNF 25 min after intranasal delivery (N = 7). (B) Intranasal delivery in nM of BDNF 60 min after intranasal delivery (N = 3).

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques:

Concentration of drug 25 min after intranasal delivery in nanograms/mL.

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: Concentration of drug 25 min after intranasal delivery in nanograms/mL.

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques: Concentration Assay

Concentration of drug 60 min after intranasal delivery in nanograms/mL.

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: Concentration of drug 60 min after intranasal delivery in nanograms/mL.

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques: Concentration Assay

Western blot examination of activation of the pAkt pathway caused by intranasal delivery of either CNTF or BDNF. (A) Representative western blot of control and CNTF-treated occipital cortex 24 and 48 h after a single intranasal application. Control pAkt protein is on the far right. HPRT was used as a loading control. (B) Densitometric examination of relative amounts of pAkt in CNTF-treated occipital cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N=6 for each time point). * indicates significantly different from control. (C) Densitometric examination of relative amounts of pAkt in BDNF-treated frontal cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N = 6 for each time point). * indicates significantly different from control.

Journal: Journal of drug targeting

Article Title: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS

doi: 10.3109/10611860903318134

Figure Lengend Snippet: Western blot examination of activation of the pAkt pathway caused by intranasal delivery of either CNTF or BDNF. (A) Representative western blot of control and CNTF-treated occipital cortex 24 and 48 h after a single intranasal application. Control pAkt protein is on the far right. HPRT was used as a loading control. (B) Densitometric examination of relative amounts of pAkt in CNTF-treated occipital cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N=6 for each time point). * indicates significantly different from control. (C) Densitometric examination of relative amounts of pAkt in BDNF-treated frontal cortex 24, 48, 72, and 96 h after a single intranasal application compared to saline-only control cortex (N = 6 for each time point). * indicates significantly different from control.

Article Snippet: [ 125 I]-labeled Neurotrophic Factors Recombinant human (rh) BDNF (molecular weight 26,984 Da), NT-4 (22,428 Da), CNTF (22,706 Da), and EPO (glycosylated form 30,400 Da) were each purchased from Cell Sciences, Inc. (Canton, MA, USA).

Techniques: Western Blot, Activation Assay, Control, Saline